Search

Olmutinib

Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

Rintodestrant

Rintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer).

Nomifensine

The approved application holder removed Merital capsules from the market on January 23, 1986. … Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia.

Halothane

A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce suffi...

Morphine glucuronide

3,4-Methylenedioxy-N-isopropylamphetamine

MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).

Cimicoxib

If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

Troxacitabine

There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.

Methyl 2,5-dihydroxycinnamate

Ergothioneine